Proteasome Inhibitors in Multiple Myeloma

Seminars in Oncology

Volumn 36, Issue SUPPL. 1, 2009, Pages

  Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CEP 18770; DEXAMETHASONE; DOXORUBICIN; HEAT SHOCK PROTEIN 90; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MELPHALAN; PERIFOSINE; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; ROMIDEPSIN; SALINOSPORAMIDE A; TANESPIMYCIN; UNCLASSIFIED DRUG; VORINOSTAT;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER RELAPSE; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; DRUG TARGETING; HUMAN; LOW DRUG DOSE; MICROENVIRONMENT; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; HISTONE DEACETYLASES; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 64849085443     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.02.001     Document Type: Article

References (50)

1. Goldberg A.L., and St John A.C. Intracellular protein degradation in mammalian and bacterial cells: Part 2. Annu Rev Biochem 45 (1976) 747-803
2. Etlinger J.D., and Goldberg A.L. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci U S A 74 (1977) 54-58
3. Hershko A., Ciechanover A., and Rose I.A. Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci U S A 76 (1979) 3107-3110
4. Ciechanover A., Finley D., and Varshavsky A. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell 37 (1984) 57-66
5. Hershko A., and Ciechanover A. The ubiquitin pathway for the degradation of intracellular proteins. Prog Nucleic Acid Res Mol Biol 33 (1986) 19-56 301
6. Hough R., Pratt G., and Rechsteiner M. Ubiquitin-lysozyme conjugates. Identification and characterization of an ATP-dependent protease from rabbit reticulocyte lysates. J Biol Chem 261 (1986) 2400-2408
7. Hough R., and Rechsteiner M. Ubiquitin-lysozyme conjugates. Purification and susceptibility to proteolysis. J Biol Chem 261 (1986) 2391-2399
8. Hough R., Pratt G., and Rechsteiner M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J Biol Chem 262 (1987) 8303-8313
9. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 Suppl 1 (2003) 3-9
10. Read M.A., Neish A.S., Luscinskas F.W., Palombella V.J., Maniatis T., and Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2 (1995) 493-506
11. Palombella V.J., Rando O.J., Goldberg A.L., and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78 (1994) 773-785
12. Chen Z., Hagler J., Palombella V.J., Melandri F., Scherer D., Ballard D., et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9 (1995) 1586-1597
13. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T.A., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87 (1996) 1104-1112
14. Shishodia S., Gutierrez A.M., Lotan R., and Aggarwal B.B. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res 65 (2005) 9555-9565
15. Sung M.H., Bagain L., Chen Z., Karpova T., Yang X., Silvin C., et al. Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells. Mol Pharmacol 74 (2008) 1215-1222
16. Podar K., Chauhan D., and Anderson K.C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23 (2009) 10-24
17. Tai Y.T., Li X.F., Breitkreutz I., Song W., Neri P., Catley L., et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66 (2006) 6675-6682
18. Hideshima T., Chauhan D., Hayashi T., Akiyama M., Mitsiades N., Mitsiades C., et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22 (2003) 8386-8393
19. Hideshima T., Chauhan D., Schlossman R., Richardson P., and Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20 (2001) 4519-4527
20. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 (2002) 16639-16647
21. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99 (2002) 4079-4086
22. McMillin D.W., Negri J., Hayden P., Weisberg E., Klippel S., Zurawska J., et al. Compartment-specific bioluminescence imaging (CD-BLI): A high-throughput approach to identify novel anti-myeloma therapies that overcome the protection of stromal cells. Haematologica 92 (2007) 65 (abstr S11.5)
23. Chauhan D., Hideshima T., and Anderson K.C. Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol 615 (2008) 251-260
24. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
25. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed multiple myeloma: an update with additional follow-up. Proceedings of the 9th Annual EHA Congress, Geneva, Switzerland, June 10-13 (2004) abstract 304
26. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
27. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
28. Richardson P.G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110 (2007) 3557-3560
29. Peles S., Fisher N.M., Gao F., Tomasson M.H., Dipersio J.F., and Vij R. A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma (MM). J Clin Oncol 24 (2006) 433s (abstr 7548)
30. Heider U., Kaiser M., Muller C., Schulz C.-O., Jakob C., Zavrski I., et al. Treatment of bortezomib increases osteoblast function in patients with multiple myeloma. Blood 106 (2005) 965a (abstr 3457)
31. Zangari M., Esseltine D., Lee C.K., Barlogie B., Elice F., Burns M.J., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131 (2005) 71-73
32. San Miguel J.F., Schlag R., Khuageva N., Shpilberg O., Dimopoulos M., Kropff M., et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 110 (2007) 31a (abstr 76)
33. Hideshima T., Bergsagel P.L., Kuehl W.M., and Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 104 (2004) 607-618
34. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8 (2005) 407-419
35. Piva R., Ruggeri B., Williams M., Costa G., Tamagno I., Ferrero D., et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111 (2008) 2765-2775
36. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
37. Harousseau J.L., Nagler A., Sonneveld P., Blade J., Hajek R., Spencer A., et al. Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. J Clin Oncol 25 (2007) 441s (abstr 8002)
38. Richardson P.G., Chanan-Khan A., Lonial S., Krishman A., Carroll M., Cropp G.F., et al. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation. Blood 110 (2007) 353a (abstr 1165)
39. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99 (2002) 4525-4530
40. Anderson K.C., Jagannath S., Jakubowiak A., Lonial S., Raje N., Schlossman R., et al. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol 26 (2008) 465s (abstr 8545)
41. Richardson P.G., Lonial S., Jakubowiak S., Jagannath S., Raje N., Avigan D.G.I.M., et al. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): a phase I/II study. J Clin Oncol 26 (2008) 459s (abstr 8520)
42. Hideshima T., Catley L., Yasui H., Ishitsuka K., Raje N., Mitsiades C., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 (2006) 4053-4062
43. Richardson P., Jakubowiak A., Wolf J., Allerton J., Zonder J., Lonial S., et al. Phase I/II report from a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma previously treated with bortezomib. Blood 110 (2007) 354a (abstr 1170)
44. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108 (2006) 3441-3449
45. Hideshima T., Bradner J.E., Chauhan D., and Anderson K.C. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 11 (2005) 8530-8533
46. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 102 (2005) 8567-8572
47. Weber D.M., Jagannath S., Mazumder A., Sobecks R., Schiller G.J., Gavino M., et al. A phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma. Blood 110 (2007) 355a (abstr 1172)
48. Badros A., Philip S., Niesvizky R., Goloubeva O., Harris C., Zweibel J., et al. Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts). Blood 110 (2007) 354a (abstr 1168)
49. Prince M., Quach H., Neeson P., Keegan M., Copeman M., Peinert S., et al. Safety and efficacy of the combination of bortezomib with the deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma: preliminary results of a phase I trial. Blood 110 (2007) 353a (abstr 1167)
50. Chauhan D., Singh A., Brahmandam M., Podar K., Hideshima T., Richardson P., et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111 (2008) 1654-1664